Each film-coated tablet contains:

Cyclobenzaprine Hydrichloride, USP 10 mg

Usual Adult Dosage:

See package outsert for dosage information

This container is not intended for household use.

Dispense contents with a child-resistant closure

(as required) and in tight, light-resistant container

as defined in the USP.

Store at 20 to 25 C (68 to 77 F); excursions

permitted to 15 to 30 C (59 to 86 F) [See

USP Controlled Room Temperature]. KEEP THIS

AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.

DESCRIPTION

Cyclobenzaprine hydrochloride, USP is a white, crystalline tricyclic amine salt with the empirical

formula C20H21N-HCl and a molecular weight of 311.9.

CLINICAL PHARMACOLOGY

Cyclobenzaprine HCl relieves skeletal muscle spasm of local origin without interfering with muscle

function. It is ineffective in muscle spasm due to central nervous system disease.

INDICATIONS AND USAGE

Cyclobenzaprine hydrochloride tablets,USP are indicated as an adjunct to rest and physical therapy for

relief of muscle spasm associated with acute, painful muscoskeletal conditions.

CONTRAINDICATIONS

Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO)

inhibitors or within 14 days after their discontinuation.

WARNINGS

Serotonin Syndrome. The development of a potentially life-threatening serotonin syndrome has been

reported with Cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective

serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic

antidepressants (TCAs), tramadol, bupropion, meperidine, verapimal,, or (MAO) inhibitors.

PRECAUTIONS

General. Because of its atropine - like action, cyclobenzaprine hydrochloride should be sued with caution

in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure and

in patients taking anticholinergic medication.

ADVERSE REACTIONS

Incidence of most common adverse reactions in the 2 double-blind, placebo controlled - 5 mg studies

(incidence of >3% on cyclobenzaprine hydrochloride 5 mg

DRUG ABUSE AND DEPENDENCE

Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be

considered when cyclobenzaprine hydrochloride is administered, even though they have not been reported

to occur with this drug. Abrupt cessation of treatment after prolonged administration rarely may

produce nausea, headache and malaise. These are not indicative of addiction.

OVERDOSAGE

Although rare, deaths may occur from overdosage with cyclobenzaprine hydrochloride.

DOSAGE AND ADMINISTRATION

For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets, USP is 5 mg three

times a day.

HOW SUPPLIED

Cyclobenzaprine hydrochloride tablets, USP 5 mg are supplied as butterscotch yellow-colored, capsule-

shaped, film-coated convex tablets, debossed with "AN40" on one side and plain on the other side.